Overview
Selectively accumulates in kidney mitochondria, protecting cardiolipin from oxidative damage.
Proposed mechanism
SS-31 targets cardiolipin in mitochondrial inner membranes, reducing ROS and preserving renal tubular function in models of kidney disease.
What the evidence supports
Most data comes from preclinical animal studies. Human clinical trial evidence is limited or absent.
Graded Animal
Evidence drawn from in vivo animal models or in vitro systems. Mechanistically informative; translation to humans is unproven.
Key citations
Representative primary sources, including results that did not favour the compound.
- [1]
SS-31 in kidney disease
· DOI:10.1681/ASN.2013040419 · 2014
- [2]
Mitochondrial peptides in nephrology
· DOI:10.1016/j.kint.2017.03.034 · 2017
- [3]
SS-31 in kidney disease (2014)
· · 0
- [4]
Mitochondrial peptides in nephrology (2017)
· · 0
Citation records in this build are illustrative placeholders for the design.
Reference information for research purposes. Not medical advice, and not a recommendation to use any compound. Many entries describe substances that are not approved for human use.